Key result
SERCA2a gene therapy is being investigated as a therapeutic approach for heart failure to address altered calcium-handling in failing cardiomyocytes.
SERCA2a gene therapy using adeno-associated viral vectors is a promising avenue of research for treating heart failure by addressing altered calcium handling.
The development of cardiac-specific adeno-associated viral vectors capable of long-term transgenic expression has opened new avenues in the therapeutic approach to heart failure. Failing cardiomyocytes demonstrate altered calcium-handling secondary to depressed expression and activity of myocardial sarcoendoplasmic reticulum calcium ATPase 2a (SERCA2a). This observation has led to a large body of research investigating the therapeutic utility of SERCA2a gene therapy in heart failure.
No takes yet. Share an insight, caveat, or question.
Papolos et al. (2012) conducted a review in Heart failure. SERCA2a gene therapy was evaluated. SERCA2a gene therapy is being investigated as a therapeutic approach for heart failure to address altered calcium-handling in failing cardiomyocytes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: